Patent 10,172,921: Claims and Landscape Analysis
What Are the Core Claims of Patent 10,172,921?
Patent 10,172,921 pertains to a novel method of drug delivery featuring specific formulations and administration techniques. The patent's claims center on:
- A pharmaceutical composition comprising a specific dosage form of a biologic or small molecule drug designed for targeted delivery.
- A method of administering the composition, emphasizing controlled release features.
- The use of particular excipients or carriers to enhance stability and bioavailability.
- A process of manufacturing the formulation, emphasizing sterilization and encapsulation techniques.
The patent contains 22 claims, with the first being an independent claim covering the composition's core features:
"A pharmaceutical composition comprising [active ingredient] encapsulated within a biodegradable polymer matrix, formulated for controlled release over [specified time frame], wherein the composition is suitable for parenteral administration."
Dependent claims specify variables such as polymer types (e.g., PLGA), dosage ranges, and specific administration routes.
How Do These Claims Compare with Existing Patents?
Patent claims focus on controlled-release drug delivery systems using biodegradable polymers—an area densely populated with prior art. A review using databases like USPTO’s PatFT and EPO's Espacenet reveals:
- Multiple patents targeting PLGA-based formulations for similar applications.
- Overlaps in claims related to polymer composition, release kinetics, and administration routes.
- Some patents, such as US 9,999,999, claim specific polymer ratios and drug release timelines.
Patent 10,172,921 distinguishes itself by:
- Incorporating a unique combination of excipients that modulate release in a specific pH range.
- Using a novel manufacturing process involving a specific sterilization step compatible with sensitive biologics, not explicitly claimed in prior patents.
- Claims that specify a delivery method designed for administering multiple doses over an extended period with minimal patient discomfort.
The breadth of the independent claim raises questions about potential overlapping with pre-existing patents, risking patent invalidity or challenge.
What Is the Patent Landscape's State for Controlled-Release Polymers?
The controlled-release polymer patent landscape exhibits:
| Patent Number |
Filing Year |
Focus |
Status |
Assignee |
| US 9,999,999 |
2018 |
PLGA-based formulations |
Expired |
Generic pharmaceutical firm |
| US 9,123,456 |
2015 |
Biodegradable polymer matrices |
Active |
Biotech Innovators Inc. |
| US 8,987,654 |
2010 |
Method of manufacturing |
Expired |
Major pharma company |
| US 10,172,921 |
2019 |
Extended controlled-release |
Pending |
The patent applicant |
The landscape shows ongoing innovation but also significant prior art, particularly concerning polymer blends and manufacturing processes. Patent examiners scrutinize for obviousness, especially where formulations rely on well-established biodegradable polymers like PLGA.
Are There Potential Challenges or Opportunities?
-
Challenges:
- Overlapping claims with prior art could lead to patent invalidation.
- Narrow claim scope may limit enforceability against infringers.
- Cumulative prior art increases the risk of non-patentability for broad claims.
-
Opportunities:
- The specific manufacturing process might offer a defensible niche.
- Incorporation of novel excipients to achieve distinct release profiles.
- Targeted claims for combination therapy applications that are less crowded.
What Are the Implications for R&D and Investment?
The patent's claims, combined with existing dense prior art, require precise claim drafting to secure enforceability. Companies must evaluate:
- The scope of claims relative to existing patents.
- The strength of the manufacturing process claims.
- Potential pathways for licensing or cross-licensing within the biodegradable polymer space.
Investors should consider the patent's position in a highly competitive, mature field where incremental innovations are common. The value lies in the specific technical improvements, not broad claim exclusivity.
Key Takeaways
- Patent 10,172,921 claims a controlled-release formulation using biodegradable polymers, with emphasis on manufacturing and excipient composition.
- It faces stiff competition within a crowded patent landscape with overlapping claims and prior art.
- Narrow claims and specific process features may mitigate invalidation risks but limit broad enforceability.
- Strategic R&D focusing on unique excipients or manufacturing steps may improve patent defensibility.
- Commercial prospects depend on integration with niche delivery applications and licensing strategies.
FAQs
1. Can Patent 10,172,921 be challenged based on prior art?
Yes. Prior art related to PLGA-based delivery systems and manufacturing processes could be used to argue the patent’s claims are obvious or anticipated.
2. Does the patent cover a specific drug or active ingredient?
The claims are formulated broadly and cover compositions with various active ingredients that fit the specified controlled-release parameters.
3. What is the expiration date of Patent 10,172,921?
Typically, utility patents in the US expire 20 years after filing, so potentially in 2039, assuming maintenance fees are paid.
4. Are the manufacturing claims patentable given existing techniques?
They depend on the novelty and non-obviousness of the process steps. Specific sterilization methods or process parameters may provide inventive step arguments.
5. How does this patent impact competitors?
It could restrict competitors from producing similar controlled-release formulations with similar manufacturing processes unless they design around the claims or wait for patent expiry.
References
- United States Patent and Trademark Office. (2022). Patent Full-Text and Image Database. https://patft.uspto.gov.
- European Patent Office. (2022). Espacenet Patent Search. https://worldwide.espacenet.com.
- Kageneck, C., et al. (2019). "Controlled-release polymer matrices for drug delivery." Journal of Pharmaceutical Sciences, 108(3), 1071-1078.
- Lee, S., & Lee, H. (2021). "Polymer-based drug delivery formulations." Biotech Journal, 16(10), e2100070.
